 The number of London-listed companies leaving the stock exchange due to takeovers is at the highest point in over a decade.
A total of 45 companies have de-listed so far this year, the highest since 2010, according to figures from Bloomberg.
Major deals include the sale of video game company Keywords Studios to private equity firm EQT, cybersecurity business Darktrace to Thoma Bravo, and Virgin Money, sold to Nationwide.
A further string of sales are expected to be completed in the coming months, such as the Czech billionaire Daniel Kretinsky’s takeover of Royal Mail owner IDS and Carlsberg’s purchase of Britvic.
It comes amid concerns that the London Stock Exchange is no longer attractive to major companies. Revolut’s chief executive Nikolay Storonsky said earlier this week that listing in London is “not rational”.
He told the 20VC podcast: “If you look at trading in the UK, you always pay a stamp duty tax, which is 0.5pc. I just don’t understand how the product which is being provided by the UK can compete with the product provided by the US.
Daily Telegraph 4th Dec |
After all the efforts expended yesterday in another memorable "fakeout" on the chart, troops are retiring to regather their strength for another assault (after Christmas?)...so barely a trade out there atm :) |
"News, news, news" would probably be more useful though Dom. |
Remember The Donald says "fight, fight, fight!". |
Defence at £4.30 battling heroically to hold the line firm - no Dad's army here but the real troops :) |
The way I had it explained to me is that JPM are an OXB broker purely so we get invited to "the" biggest investor healthcare conference of the year. Pay JPM to be your broker and you get an invite, but a small cap bio is not really a stock that JPM would cover in depth, so you get what you get which is basically this.
Novo boomed massively on being the first to market with the GLP-1 weight loss drug in that biggest market. I think their up and down since is to do with people trying to work out what the real price is rather than anything post-covid related. |
P75/DC, keep the small punters out....make it all look so dull and boring and when we are at deemed "suitable" price flex to uber bullish in the broker reports, we all buy in when they sell out....is that not how it goes small punters buy high and sell low? |
Nice jump. Big trade? |
Lack of the means to do their diligent research? |
I just don’t get why the brokers are being so pessimistic for share price targets. |
If so GJ, perhaps move on and find a different broker.... |
Is that an update from today. If so and if JPMC (joint corporate broker) then a "neutral" recommendation is a poor update. |
Harry, the Novo share price has been some surprise recently to fall from 1.40 to 1.00 and now back up a little. You have to say at some point this is all look very over sold and due a recovery bounce across the sector. I see the EWI trust is moving ahead quite a bit now which supports the view that parts of the small cap bio is drawing some interest too. Traders are happy to take quite a decent number of shares for only a small discount to the bid, so there are buyers here atm even though the market looks so thin.... |
SMALL CAP
----------
JPMorgan raises Oxford BioMedica price target to 490 (450) pence - 'neutral' |
been a very tough year for the health sector 2024 YTD vs S&P 500 - so we are swimming well against the tide as they say...keeps expectations realistic for me I guess... |
A day of completely piddling trades. |
Is it quite unusual, or surprising, that the track of the share price each day is so similar. Up first thing, then promptly down significantly, fairly flat during the afternoon, then up at end of day. |
Where on earth do you get your information from luminaire? At worst he has made an amusing aside referencing Trump.
On the other hand I prefer Trump and his cohort of (relatively) amature appointees to the failed bunch that have previously enjoyed the power in the USA. So far, he has not used the Law as an instrument to attack his enemies, started a war, or imprisoned his political enemies. Although he has criticised big pharma (or rather his allies have) but can you say without crossing your fingers that they always behave well? |
Up there with your previous post that OXB is going down and that I personally should take some responsibility for it. Not aged well with next year being record sales and a profit.
I'm all for release into the community but I don't think you should be given internet access. |
Not long now and Harry's mate becomes the most powerful man in the world appointing science denying conspiracy theorists who want to decimate the pharma industry. |
I'm all for it and good luck to them Phil. We know these first 3 weeks of December are almost always a very slow time of year, so anything to cheer up the festivities is more than welcome. My one humbug point would be the obvious one that if this initiative had come from the board then it would be on the main website and not LinkedIn, but someone is giving it a go and well done to them. Every little helps - as one of the supermarkets used to say.
My focus this week is what the EU regulator says about the Novo purchase of Catalent, with the deadline being Friday. If that does get rubber stamped then that just leaves the FTC and if they also say yes (two big ifs there I know) then I continue to have this feeling that Novo's plan for the C> arm of Catalent also involves OXB. |
Harry, I think they’ve nicked your idea!!
𝗝𝗼𝗶𝗻 𝘂𝘀 𝗳𝗼𝗿 "𝟭𝟮 𝗗𝗮𝘆𝘀 𝗼𝗳 𝗢𝗫𝗕"!
This festive season, we’re celebrating OXB’s incredible achievements, milestones, and innovations with a nod to the classic “12 Days of Christmas” song, thought to have roots in both English and French traditions—a fitting reflection of our global presence, which includes two sites in France!
LinkedIn
Running from December 1st to December 12th, we’ll share a daily post revealing a key milestone or fact about OXB. From ground-breaking scientific advancements to state-of-the-art manufacturing, we’re excited to highlight how we’re driving the cell and gene therapy field forward. |
Register for streaming realtime charts, analysis tools, and prices.
Hot Features
Premium
